Management of Adult Recurrent Respiratory Papillomatosis with Oral Acyclovir Following Micro Laryngeal Surgery: A Case Series

  • Jagdish Chaturvedi
  • V. Sreenivas
  • V. Hemanth
  • R. Nandakumar
Clinical Report


To demonstrate the role of oral acyclovir in monthly regimes after microdebrider assisted excision in 3 patients with adult recurrent respiratory papillomatosis (ARRP). Three patients with ARRP who presented to a tertiary referral hospital in stridor were initially treated with a tracheostomy in order to secure airway. On further evaluation by videolaryngoscopy extensive bilateral laryngeal papillomatosis was noted with history of similar conditions in the past for which they were repeatedly operated. They were admitted and underwent Microlaryngeal surgery and laryngeal microdebrider assisted surgery under general anesthesia. Post operatively a course of oral acyclovir at 800 mg/5 times/day for 5 days was administered. On repeat assessment with videolaryngoscopy at monthly intervals a complete remission of the disease was noted with no residual disease at the end of 1 year in 2 cases. One case had a recurrence. Renal parameters were monitored periodically. It may be concluded that the action of anti viral drugs at regular intervals in addition to a short course of oral steroids lead to rapid recovery and prevented latent virus activation within the laryngo tracheal system hence maintaining long term improvement. This can avoid multiple laryngeal surgeries, repeated respiratory emergencies and risk for malignant transformation in the future thereby reducing morbidity and effect on quality of life.


Adult recurrent respiratory papillomatosis (ARRP) Papillomatosis Acyclovir Human papilloma virus (HPV) 


  1. 1.
    Smith EM, Pignatari SSN, Gray SD, Haugen TH, Turek LP (1993) Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction. Arch Otolaryngol Head Neck Surg 119:554–557PubMedCrossRefGoogle Scholar
  2. 2.
    Kramer SS, Wehunt WD, Stocker JT, Kashima H (1985) Pulmonary manifestations of juvenile laryngotracheal papillomatosis. AJR Am J Roentgenol 144:687–694PubMedCrossRefGoogle Scholar
  3. 3.
    Lee E, Katakami N, Sakamoto H et al (1986) A case of papillomatosis of larynx and trachea. Kikanshi 8:97–102Google Scholar
  4. 4.
    Steinbrook R (2006) The potential of human papillomavirus vaccines. N Engl J Med 354:1109–1112PubMedCrossRefGoogle Scholar
  5. 5.
    Szeps M, Dahlgren L, Aaltonen LM, Öhd J (2005) Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment. J Gen Virol 86:1695–1702PubMedCrossRefGoogle Scholar
  6. 6.
    Deunas L, Alcantud V, Alvarez F (1997) Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme. J Laryngol Otol 1997(111):134–140Google Scholar
  7. 7.
    Kimberlin DW (2004) Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res 63:141–151PubMedCrossRefGoogle Scholar
  8. 8.
    Drennan JM, Douglas AC (1965) Solitary papilloma of a bronchus. J Clin Pathol 18:401–402PubMedCrossRefGoogle Scholar
  9. 9.
    Singer DB, Greenberg SD, Harrison GM (1966) Papillomatosis of the lung. Am Rev Respir Dis 94:777–783PubMedGoogle Scholar
  10. 10.
    Steinberg BM, Topp W, Schneider PS, Abramson AL (1983) Laryngeal papillomavirus infection during clinical remission. N Engl J Med 308:1261–1264PubMedCrossRefGoogle Scholar
  11. 11.
    Abramson AL, Nouri M, Mullooly V, Fisch G, Steinberg BM (2004) Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 72:473–477PubMedCrossRefGoogle Scholar
  12. 12.
    Broker TR, Jin G, Croom-Rivers A et al (2001) Viral latency: the papillomavirus model. Dev Biol (Basel). 106:443–451PubMedGoogle Scholar
  13. 13.
    Bonagura VR, Hatam L, DeVoti J, Zeng F, Steinberg BM (1999) Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and TH1/TH2 cytokine imbalance. Clin Immunol. 93:302–311PubMedCrossRefGoogle Scholar
  14. 14.
    DeVoti JA, Steinberg BM, Rosenthal DW et al (2004) Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin Diagn Lab Immunol 11:538–547PubMedCentralPubMedGoogle Scholar
  15. 15.
    Shikowitz MJ, Abramson AL, Steinberg BM, Voti JD (2005) Clinical trial of photodynamic therapy with meso-tetra (Hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 131:99–105PubMedCrossRefGoogle Scholar
  16. 16.
    Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E, Feenstra L (1998) Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1- (3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol 54:219–225PubMedCrossRefGoogle Scholar
  17. 17.
    Dallimore NS (1985) Squamous bronchial carcinoma arising in a case of multiple juvenile papillomatosis. Thorax 40:797–798PubMedCrossRefGoogle Scholar

Copyright information

© Association of Otolaryngologists of India 2012

Authors and Affiliations

  • Jagdish Chaturvedi
    • 1
    • 2
  • V. Sreenivas
    • 1
  • V. Hemanth
    • 1
  • R. Nandakumar
    • 1
  1. 1.Department of Otolaryngology and Head and Neck SurgerySt John’s Medical College and HospitalBangaloreIndia
  2. 2.BangaloreIndia

Personalised recommendations